Salarius Pharmaceuticals, Inc. (SLRX)
NASDAQ: SLRX · Real-Time Price · USD
0.7000
-0.0540 (-7.16%)
At close: Apr 1, 2025, 4:00 PM
0.7298
+0.0298 (4.26%)
After-hours: Apr 1, 2025, 4:38 PM EDT

Company Description

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need.

Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma.

The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors.

It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities.

The company is headquartered in Houston, Texas.

Salarius Pharmaceuticals, Inc.
Salarius Pharmaceuticals logo
Country United States
Industry Biotechnology
Sector Healthcare
Employees 2
CEO David Arthur

Contact Details

Address:
2450 Holcombe Boulevard, Suite X
Houston, Texas 77021
United States
Phone 832 834 9144
Website salariuspharma.com

Stock Details

Ticker Symbol SLRX
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001615219
CUSIP Number 79400X404
ISIN Number US79400X4043
Employer ID 46-5087339
SIC Code 2834

Key Executives

Name Position
David J. Arthur M.B.A. Chief Executive Officer, President and Director
Mark J. Rosenblum CPA Executive Vice President of Finance and Chief Financial Officer

Latest SEC Filings

Date Type Title
Mar 28, 2025 8-K Current Report
Mar 21, 2025 10-K Annual Report
Mar 11, 2025 8-K Current Report
Mar 11, 2025 424B5 Filing
Jan 21, 2025 S-1 General form for registration of securities under the Securities Act of 1933
Jan 17, 2025 8-K Current Report
Jan 13, 2025 424B3 Prospectus
Jan 13, 2025 8-K Current Report
Dec 27, 2024 EFFECT Notice of Effectiveness
Dec 27, 2024 D Notice of Exempt Offering of Securities